Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00956)
Name
Clofazimine
Synonyms    Click to Show/Hide the Synonyms of This API
clofazimine; 2030-63-9; Lamprene; Lampren; Chlofazimine; Clofazimina; Clofaziminum; B 663 (Pharmaceutical); Clofaziminum [INN-Latin]; Clofazimina [INN-Spanish]; NSC-141046; G 30320; B-663; N,5-bis(4-chlorophenyl)-3-propan-2-yliminophenazin-2-amine; UNII-D959AE5USF; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin; B 663; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-phenazine; 3-(p-Chloroanilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; D959AE5USF; CHEBI:3749; CHEMBL1083384; G-30320; 2-Phenazinamine, 3,5-dihydro-N,5-bis(4-chlorophenyl)-3-((1-methylethyl)imino)-; 2-Phenazinamine, N,5-bis(4-chlorophenyl)-3,5-dihydro-3-((1-methylethyl)imino)-; 2-Phenazinamine, N,5-bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-2-phenazinamine; Clofazimine, 98%; MFCD00056793; MMV687800; NSC141046; Phenazine, 2,10-dihydro-3-(p-chloroanilino)-10-(p-chlorophenyl)-2-(isopropylimino)-; Phenazine, 3-(p-chloroanilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-; NCGC00016600-01; CAS-2030-63-9; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(isopropylimino)phenazin-2-amine; 2-Phenazinamine,N,5-bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-; N,5-bis(4-chlorophenyl)-3-(propan-2-ylimino)-3,5-dihydrophenazin-2-amine; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; Riminophenazine; C27H22Cl2N4; (E)-N,5-bis(4-chlorophenyl)-3-(isopropylimino)-3,5-dihydrophenazin-2-amine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(isopropyliaino)phenazin-2-amine; B 663 (VAN); (3Z)-N,5-bis(4-chlorophenyl)-3-[(1-methylethyl)imino]-3,5-dihydrophenazin-2-amine; Lamprene (TN); SMR000058704; B 663, pharmaceutical; SR-05000001807; EINECS 217-980-2; NSC 141046; BRN 0060420; Clofazimine (JAN/USP/INN); (3E)-N,5-bis(4-chlorophenyl)-3-isopropylimino-phenazin-2-amine; Liposome-encapsulated clofazimine; Clofazimine [USAN:USP:INN:BAN]; Prestwick_685; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin [German]; SMP2_000339; (non-d)Clofazimine-d7; B663; CPD000058704; Prestwick0_000376; Prestwick1_000376; Prestwick2_000376; Prestwick3_000376; DSSTox_CID_2839; B. 663; cid_2794; CHEMBL1292; DSSTox_RID_76752; BIDD:PXR0147; DSSTox_GSID_22839; SCHEMBL26757; SCHEMBL26758; BSPBio_000531; 4-25-00-03033 (Beilstein Handbook Reference); CFZ; MLS000028617; MLS001424318; MLS006010789; SPBio_002452; BPBio1_000585; GTPL9184; SCHEMBL5663361; CHEMBL1369407; DTXSID7022839; HMS1569K13; HMS2052B05; HMS2093J10; HMS2096K13; HMS2231B04; HMS3370N05; HMS3394B05; HMS3652A16; HMS3713K13; KUC109573N; Pharmakon1600-01505974; AMY22515; BCP07792; HY-B1046; KSC-27-052A; Tox21_110516; BDBM50318909; BDBM50378783; NSC759283; s4107; ZINC17953024; AKOS015896438; AKOS026749881; ZINC100037101; ZINC253916263; CCG-101159; CCG-269477; CS-4567; DB00845; KS-1412; MCULE-1387160272; NC00409; NSC-759283; NCGC00016600-02; NCGC00016600-03; NCGC00016600-04; NCGC00016600-05; NCGC00016600-07; NCGC00016600-08; NCGC00016600-09; NCGC00179529-01; AK544295; SMR004701474; Clofazimine 100 microg/mL in Acetonitrile; Phenazine,10-dihydro-2-(isopropylimino)-; SBI-0206865.P001; FT-0657414; ST51014966; SW196840-4; Z3118; A16462; C06915; D00278; 030C639; A814428; Q418611; J-013203; SR-05000001807-1; SR-05000001807-2; BRD-K56614220-001-10-9; Z2037279473; Clofazimine, European Pharmacopoeia (EP) Reference Standard; N,5-bis(4-chlorophenyl)-3-propan-2-ylimino-2-phenazinamine; N,5-bis(4-chlorophenyl)-3-propan-2-ylimino-phenazin-2-amine; Clofazimine, United States Pharmacopeia (USP) Reference Standard; 2-p-Chloranilino-5-p-chlorphenyl-3,5-dihydro-3-isopropylimino-phenazin; N,5-bis(4-chlorophenyl)-3-(isopropylimino)-3,5-dihydrophenazin-2-amine; (4-Chloro-phenyl)-[5-(4-chloro-phenyl)-3-isopropylimino-3,5-dihydro-phenazin-2-yl]-amine; 2-Phenazinamine,5-bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-; 2-Phenazinamine,5-dihydro-N,5-bis(4-chlorophenyl)-3-[(1-methylethyl)imino]-; 4-chloro-N-(5-(4-chlorophenyl)-3,5-dihydro-3-isopropyliminophenazin-2-yl)aniline;; Clofazimine for system suitability, European Pharmacopoeia (EP) Reference Standard; N,5-Bis(4-chlorophenyl)-3-([1-methylethyl]imino)-3,5-dihydro-2-phenazinamine #; N,5-bis(4-chlorophenyl)-3-[(propan-2-yl)imino]-3,5-dihydrophenazin-2-amine; Phenazine,10-dihydro-3-(p-chloroanilino)-10-(p-chlorophenyl)-2-(isopropylimino)-; (4-chlorophenyl)[5-(4-chlorophenyl)-3-(2-methyl-1-azapropylidene)(5-hydrophena zin-2-yl)]amine
Clinical Status
Approved
PubChem CID
2794
Formula
C27H22Cl2N4
Canonical SMILES
CC(C)N=C1C=C2C(=NC3=CC=CC=C3N2C4=CC=C(C=C4)Cl)C=C1NC5=CC=C(C=C5)Cl
InChI
1S/C27H22Cl2N4/c1-17(2)30-24-16-27-25(15-23(24)31-20-11-7-18(28)8-12-20)32-22-5-3-4-6-26(22)33(27)21-13-9-19(29)10-14-21/h3-17,31H,1-2H3
InChIKey
WDQPAMHFFCXSNU-UHFFFAOYSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=2794"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 473.4 Topological Polar Surface Area 40
XlogP 7.1 Complexity 829
Heavy Atom Count 33 Rotatable Bond Count 4
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 4
Full List of Drug Formulations (DFMs) Containing This API
          Clofazimine 100mg capsule Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Beeswax; Butylated Hydroxytoluene; Citric Acid; Ethyl Vanillin; Gelatin; Glycerin; Iron Oxide; Lecithin; P-Methoxy Acetophenone; Parabens; Plant Oils; Propylene Glycol; Ethyl Parahydroxybenzoate Sodium; Propyl Parahydroxybenzoate Sodium; Ethylvanillin; Gelatin; Glycerol; Black Iron Oxide; Red Iron Oxide; P-Methoxy Acetophenone
                   Dosage Form Capsule
                   Company Novartis
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Butylated hydroxytoluene DIG Info Carbonic anhydrase II (Ki = 630 nM) [1]
methylparaben DIG Info Carbonic anhydrase VII (Ki = 780 nM) [2]
Ethylparaben DIG Info Estrogen receptor beta (EC50 = 1860 nM) [3]
Kyselina citronova DIG Info Perilipin-1 (IC50 = 3708 nM) [4]
Ethyl vanillin DIG Info Aldehyde dehydrogenase 5A1 (IC50 = 15600 nM) [5]
Propylparaben sodium DIG Info Estrogen receptor alpha (EC50 = 38200 nM) [3]
Propylene glycol DIG Info Albendazole monooxygenase (Inhibition ratio < 20 %) [6]
Gelatin DIG Info Mephenytoin 4-hydroxylase (EC50 = 20.5 uM) [7]
Soybean lecithin DIG Info Albendazole monooxygenase (IC50 = 6.61 mg.mL-1) [6]
References
1 Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols. Bioorg Med Chem. 2009 Apr 15; 17(8):3207-11.
2 Mono-/dihydroxybenzoic acid esters and phenol pyridinium derivatives as inhibitors of the mammalian carbonic anhydrase isoforms I, II, VII, IX, XII and XIV. Bioorg Med Chem. 2013 Mar 15; 21(6):1564-9.
3 Discovery of natural estrogen receptor modulators with structure-based virtual screening. Bioorg Med Chem Lett. 2013 Jun 1; 23(11):3329-33.
4 PubChem BioAssay data set.
5 Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives. Bioorg Med Chem Lett. 2006 Feb; 16(3):592-5.
6 Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm. 2008 Sep;70(1):279-88.
7 Mediation of in vitro cytochrome p450 activity by common pharmaceutical excipients. Mol Pharm. 2013 Jul 1;10(7):2739-48.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.